Aging‐Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model‐Based Assessment of Amlodipine
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Jie En Valerie Sia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Amlodipine, Cytochrome P-450 CYP3A, Aging, Models, Biological. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Gates Foundation, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Aging‐related alterations in hepatic enzyme activity, particularly of the CYP3A, significantly impact drug efficacy and safety in older adults, making it essential to understand how aging affects CYP function for optimal drug therapy. The exogenous probe substrate method, a minimally invasive approach to assess liver metabolic enzyme activity in vivo , is effective in studying these changes. Amlodipine being extensively metabolized (> 90%) in the liver, primarily via cytochrome P450 enzyme CYP3A was selected as a probe to investigate and quantify the factors affecting the aging‐related changes of CYP3A in the Chinese older population. Amlodipine concentration data were collected from an ongoing noninterventional clinical study conducted at Peking University Third Hospital. A physiologically‐based pharmacokinetic modeling approach, grounded in population pharmacokinetic (PPK) analysis, was employed to physiologically quantify the aging‐related changes in CYP3A function. A total of 132 amlodipine concentrations from 69 patients were obtained from the clinical study. PPK analysis shows that frailty phenotype but not age is a significant influence and frail patients have 37% greater plasma amlodipine exposure than nonfrail patients. This difference in CYP3A function may be attributed to a 63.2% lower CYP3A relative abundance in the frail patients, compared with that in the nonfrail patients. In the context of dose selection for older adults, focusing on frailty rather than chronological age should be recognized as a more relevant approach, because frailty might more accurately reflect the individual's biological age. Our study suggested a need to shift the research focus from chronological age to biological age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
- Geriatrics Department, Peking University Third Hospital, Beijing, China.
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
- Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
- Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Jie En Valerie Sia, Cheng Cui, Dongyang Liu
Förderung
- National Natural Science Foundation of China
- Gates Foundation
- Bill and Melinda Gates Foundation
Zitieren
APA
Valerie Sia, J. E., Lai, X., Mak, W. Y., Wu, X., Zhang, F., Cui, C., Liu, D., & Xiang, X. (2024). Aging‐Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model‐Based Assessment of Amlodipine. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3347
Vancouver
Valerie Sia JE, Lai X, Mak WY, Wu X, Zhang F, Cui C, et al. Aging‐Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model‐Based Assessment of Amlodipine. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3347
BibTeX
@article{ValerieSia2024,
author = {Valerie Sia, Jie En and Lai, Xuan and Mak, Wen Yao and Wu, Xinyi and Zhang, Fan and Cui, Cheng and Liu, Dongyang and Xiang, Xiaoqiang},
title = {Aging‐Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model‐Based Assessment of Amlodipine},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3347}
}
EUVIMED